Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002017 · ClinicalTrials.gov registry record · NA
Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2
A NA study, sponsored by Rockefeller University.
- Completed
- Registry status
- NA
- Development phase
NCT00002017 is a NA study that has completed, run by Rockefeller University.
The verdict
NCT00002017, a NA study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To evaluate the safety and immunological effects of polyethylene glycolated-interleukin-2 (PEG-IL-2) on asymptomatic (without symptoms) HIV-seropositive patients who are taking zidovudine (AZT). To enhance measures of immune function with well-tolerated doses of PEG-IL-2, an immunomodulator, in a regimen designed to allow its use in outpatients with normal daily activity (i.e., full-time employment, etc.). Recombinant IL-2 (without PEG modification) was administered to HIV-infected patients by daily intradermal injection. At the low doses used, this was non-toxic, well-tolerated, and gave a systemic response as measured by natural killer cell and lymphokine-activated killer cell activity, but required daily administration. In the current study, the PEG modification of IL-2 is used since it has a much longer prolonged half-life compared with the non-PEG compound, without loss of functional activity.
Interventions
- DRUG Interleukin-2, Polyethylene Glycolated
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002017
The ClinicalTrials.gov registry entry for NCT00002017 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interleukin-2, Polyethylene Glycolated is the first listed.
NCT00002017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002017 about?
NCT00002017 is a clinical study titled "Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2". To evaluate the safety and immunological effects of polyethylene glycolated-interleukin-2 (PEG-IL-2) on asymptomatic (without symptoms) HIV-seropositive patients who are taking zidovudine (AZT). To enhance measures of immune function with well-tolerated doses of PEG-IL-2, an immunomodulator, in a re...
What is the current status of trial NCT00002017?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002017?
The interventions under investigation include: Interleukin-2, Polyethylene Glycolated (DRUG).
Who is sponsoring clinical trial NCT00002017?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.